A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Conditions: Lung Cancer; Camrelizumab Interventions: Drug: Camrelizumab + chemotherapy+Thalidomide; Drug: Camrelizumab + chemotherapy+placebo Sponsors: Tongji University; Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials